|Table of Contents|

Research progress on the relationship between intestinal flora and lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 03
Page:
569-576
Research Field:
Publishing date:

Info

Title:
Research progress on the relationship between intestinal flora and lung cancer
Author(s):
JIAO Qianqian; ZHU Jiwei; PAN Lei
Department of Respiratory and Critical Care Medicine,Binzhou Medical University Hospital，Shandong Binzhou 256003，China.
Keywords:
intestinal flora; lung cancer; treatment; research progress
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2024.03.034
Abstract:
Lung cancer is one of the deadliest and most common malignant tumors in the world.The major treatments for lung cancer include surgery,chemotherapy,radiotherapy,targeted therapy and immunotherapy,etc.With the maturity and improvement of these treatment schemes,the prognosis of lung cancer patients has improved significantly.Especially,the invention of targeted therapies has significantly improved the survival of lung cancer patients.However,studies show that lung cancer remains the leading cause of cancer death in the Chinese population,and how to reduce the incidence and improve the prognosis of lung cancer is still a hot topic.In recent years,a growing number of scholars have started to pay attention to the relationship between intestinal flora and lung cancer.Numerous studies have found differences in the composition and abundance of intestinal flora in lung cancer patients compared to the healthy population,and intestinal flora itself or its metabolites can influence the microenvironment of lung tumors,the efficacy of lung cancer therapeutic agents and treatment-related side effects through the regulation of multiple systems of the host.The influence of intestinal flora has to be taken into account in the development of lung cancer and the subsequent treatment of the tumor.

References:

［1］BACKHED F,LEY RE,SONNENBURG JL,et al.Host-bacterial mutualism in the human intestine［J］.Science,2005,307 (5717):1915-1920.
［2］TRIVEDI R,BARVE K.Gut microbiome a promising target for management of respiratory diseases［J］.Biochem J,2020,477(14):2679-2696.
［3］FINNICUM CT,RAHAL Z,HASSANE M,et al.Pathogenesis of tobacco-associated lung adenocarcinoma is closely coupled with changes in the gut and lung microbiomes［J］.Int J Mol Sci,2022,23(18):10930.
［4］CARBONE C,PIRO G,DI NOIA V,et al.Lung and gut microbiota as potential hidden driver of immunotherapy efficacy in lung cancer［J］.Mediators Inflamm,2019,2019:7652014.
［5］ZHUANG H,CHENG L,WANG Y,et al.Dysbiosis of the gut microbiome in lung cancer［J］.Front Cell Infect Microbiol,2019,9:112.
［6］LIU F,LI J,GUAN Y,et al.Dysbiosis of the gut microbiome is associated with tumor biomarkers in lung cancer［J］.Int J Biol Sci,2019,15(11):2381-2392.
［7］MATSON V,CHERVIN CS,GAJEWSKI TF.Cancer and the microbiome-influence of the commensal microbiota on cancer,immune responses, and immunotherapy［J］.Gastroenterology,2021,160 (2):600-613.
［8］ERDMAN SE,POUTAHIDIS T.Gut microbiota modulate host immune cells in cancer development and growth［J］.Free Radic Biol Med,2017,105:28-34.
［9］BOESTEN RJ,SCHUREN FH,WILLEMSEN LE,et al.Bifidobacterium breve-HT-29 cell line interaction:modulation of TNF-alpha induced gene expression［J］.Benef Microbes,2011,2(2):115-128.
［10］ZITVOGELL,DAILLERE R,ROBERTI MP,et al.Anticancer effects of the microbiome and its products［J］.Nat Rev Microbiol,2017,15(8):465-478.
［11］WANG S,LIU K,SENEVIRATNE CJ,et al.Lipoteichoic acid from an enterococcus faecalis clinical strain promotes TNF-alpha expression through the NF-kappaB and p38 MAPK signaling pathways in differentiated THP-1 macrophages［J］.Biomed Rep,2015,3(5):697-702.
［12］SHANG GS,LIU L,QIN YW.IL-6 and TNF-alpha promote metastasis of lung cancer by inducing epithelial-mesenchymal transition［J］.Oncol Lett,2017,13(6):4657-4660.
［13］ZHOU YJ,ZHAO DD,LIU H,et al.Cancer killers in the human gut microbiota:diverse phylogeny and broad spectra［J］.Oncotarget,2017,8(30):49574-49591.
［14］WEI YF,HUANG MS,HUANG CH,et al.Impact of gut dysbiosis on the risk of non-small-cell lung cancer［J］.Int J Environ Res Public Health,2022,19(23):15991.
［15］OTOSHI T,NAGANO T,PARK J,et al.The gut microbiome as a biomarker of cancer progression among female never-smokers with lung adenocarcinoma［J］.Anticancer Res,2022,42(3):1589-1598.
［16］GUTIERREZ-DIAZ I,FERNANDEZ-NAVARRO T,SANCHEZ B ,et al.Mediterranean diet and faecal microbiota:a transversal study［J］.Food Funct,2016,7(5):2347-2356.
［17］DOBSON A,COTTER PD,ROSS RP,et al.Bacteriocin production:a probiotic trait［J］.Appl Environ Microbiol,2012,78(1):1-6.
［18］PATIL SM,KUNDA NK.Nisin ZP,an antimicrobial peptide,induces cell death and inhibits non-small cell lung cancer (NSCLC) progression in vitro in 2D and 3D cell culture［J］.Pharm Res,2022,39(11):2859-2870.
［19］AKIRA S,UEMATSU S,TAKEUCHI O.Pathogen recognition and innate immunity［J］.Cell,2006,124 (4):783-801.
［20］ZITVOGEL L,MA Y,RAOULT D,et al.The microbiome in cancer immunotherapy:diagnostic tools and therapeutic strategies［J］.Science,2018,359 (6382):1366-1370.
［21］KIM DH.Gut microbiota-mediated drug-antibiotic interactions［J］.Drug Metab Dispos,2015,43 (10):1581-1589. ［22］FLUCKIGER A,DAILLERE R,SASSI M,et al.Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage［J］.Science,2020,369 (6506):936-942.
［23］ZHAO H,LI D,LIU J,et al.Bifidobacterium breve predicts the efficacy of anti-PD-1 immunotherapy combined with chemotherapy in Chinese NSCLC patients［J］.Cancer Med,2022,12(5):6325-6336.
［24］CHENG M,QIAN L,SHEN G,et al.Microbiota modulate tumoral immune surveillance in lung through a gammadeltaT17 immune cell-dependent mechanism［J］.Cancer Res,2014,74(15):4030-4041.
［25］PENSEC C,GILLAIZEAU F,GUENOT D,et al.Impact of pemetrexed chemotherapy on the gut microbiota and intestinal inflammation of patient-lung-derived tumor xenograft (PDX) mouse models［J］.Sci Rep,2020,10(1):9094.
［26］CRISTIANO C,CUOZZO M,CORETTI L,et al.Oral sodium butyrate supplementation ameliorates paclitaxel-induced behavioral and intestinal dysfunction［J］.Biomed Pharmacother,2022,153:113528.
［27］VIAUD S,SACCHERI F,MIGNOT G,et al.The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide［J］.Science,2013,342(6161):971-976.
［28］ZITVOGEL L,GALLUZZI L,VIAUD S,et al.Cancer and the gut microbiota:an unexpected link［J］.Sci Transl Med,2015,7(271):271.
［29］GUI QF,LU HF,ZHANG CX,et al.Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model［J］.Genet Mol Res,2015,14(2):5642-5651.
［30］KONISHI H,FUJIYA M,TANAKA H,et al.Probiotic-derived ferrichrome inhibits colon cancer progression via JNK-mediated apoptosis［J］.Nat Commun,2016,7:12365.
［31］PIETROCOLA F,POL J,VACCHELLI E,et al.Caloric restriction mimetics enhance anticancer immunosurveillance［J］.Cancer Cell,2016,30(1):147-160.
［32］ARANDA F,BLOY N,PESQUET J,et al.Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer［J］.Oncogene,2015,34(23):3053-3062.
［33］POUNCEY AL,SCOTT AJ,ALEXANDER JL,et al.Gut microbiota,chemotherapy and the host:the influence of the gut microbiota on cancer treatment［J］.Ecancermedicalscience,2018,12:868.
［34］HESHIKI Y,VAZQUEZ-URIBE R,LI J,et al.Predictable modulation of cancer treatment outcomes by the gut microbiota［J］.Microbiome,2020,8(1):28.
［35］WOJAS-KRAWCZYK K,KALINKA E,GRENDA A,et al.Beyond PD-L1 markers for lung cancer immunotherapy［J］.Int J Mol Sci,2019,20(8):1915.
［36］JIN Y,DONG H,XIA L,et al.The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in chinese patients with NSCLC［J］.J Thorac Oncol,2019,14(8):1378-1389.
［37］GRIFFIN ME,ESPINOSA J,BECKER JL,et al.Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy［J］.Science,2021,373(6558):1040-1046.
［38］ANDREWS MC,DUONG CPM,GOPALAKRISHNAN V,et al.Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade［J］.Nat Med,2021,27(8):1432-1441.
［39］TOMITA Y,IKEDA T,SAKATA S,et al.Association of probiotic clostridium butyricum therapy with survival and response to immune checkpoint blockade in patients with lung cancer［J］.Cancer Immunol Res,2020,8(10):1236-1242.
［40］WAN L,WU C,WU Q,et al.Impact of probiotics use on clinical outcomes of immune checkpoint inhibitors therapy in cancer patients［J］.Cancer Med,2023,12(2):1841-1849.
［41］DEROSA L,HELLMANN MD,SPAZIANO M,et al.Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer［J］.Ann Oncol,2018,29(6):1437-1444.
［42］KATAYAMA Y,YAMADA T,TANIMURA K,et al.Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer［J］.Thorac Cancer,2019,10(3):526-532.
［43］ZHAO S,GAO G,LI W,et al.Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer［J］.Lung Cancer,2019,130:10-17.
［44］OUAKNINE KRIEF J,HELLY DE TAURIERS P,DUMENIL C,et al.Role of antibiotic use,plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab［J］.J Immunother Cancer,2019,7(1):176.
［45］HAKOZAKI T,OKUMA Y,OMORI M,et al.Impact of prior antibiotic use on the efficacy of nivolumab for non-small cell lung cancer［J］.Oncol Lett,2019,17(3):2946-2952.
［46］RUIZ-PATINO A,BARRON F,CARDONA AF,et al.Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP)［J］.Thorac Cancer,2020,11(9):2552-2560.
［47］TINSLEY N,ZHOU C,TAN G,et al.Cumulative antibiotic use significantly decreases efficacy of checkpoint inhibitors in patients with advanced cancer［J］.Oncologist,2020,25(1):55-63.
［48］GALLI G,TRIULZI T,PROTO C,et al.Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer［J］.Lung Cancer,2019,132:72-78.
［49］ZHANG YB,LIU SJ,HU ZD,et al.Increased th17 activation and gut microbiota diversity are associated with pembrolizumab-triggered tuberculosis［J］.Cancer Immunol Immunother,2020,69(12):2665-2671.
［50］MATSON V,FESSLER J,BAO R,et al.The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients［J］.Science,2018,359(6371):104-108.
［51］ROUTY B,LE CHATELIER E,DEROSA L,et al.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors［J］.Science,2018,359(6371):91-97.
［52］DEROSA L,ROUTY B,THOMAS AM,et al.Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer［J］.Nat Med,2022,28(2):315-324.
［53］CVETKOVIC L,REGIS C,RICHARD C,et al.Physiologic colonic uptake of 18F-FDG on PET/CT is associated with clinical response and gut microbiome composition in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors［J］.Eur J Nucl Med Mol Imaging,2021,48(5):1550-1559.
［54］SIVAN A, CORRALES L,HUBERT N,et al.Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy［J］.Science,2015,350(6264):1084-1089.
［55］BOTTICELLI A,VERNOCCHI P,MARINI F,et al.Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment［J］.J Transl Med,2020,18(1):49.
［56］VETIZOU M,PITT JM,DAILLERE R,et al.Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota［J］.Science,2015,350(6264):1079-1084.
［57］LI W,DENG Y,CHU Q,et al.Gut microbiome and cancer immunotherapy［J］.Cancer Lett,2019,447:41-47.
［58］LIU T,XIONG Q,LI L,et al.Intestinal microbiota predicts lung cancer patients at risk of immune-related diarrhea［J］.Immunotherapy,2019,11(5):385-396.
［59］TIAN Y,LI M,SONG W,et al.Effects of probiotics on chemotherapy in patients with lung cancer［J］.Oncol Lett,2019,17 (3):2836-2848.
［60］GEIS AL,FAN H,WU X,et al.Regulatory T-cell response to enterotoxigenic bacteroides fragilis colonization triggers IL17-dependent colon carcinogenesis［J］.Cancer Discov,2015,5(10):1098-1109.
［61］ZHANG M,ZHOU H,XU S,et al.The gut microbiome can be used to predict the gastrointestinal response and efficacy of lung cancer patients undergoing chemotherapy［J］.Ann Palliat Med,2020,9(6):4211-4227.
［62］QIAN X,ZHANG HY,LI QL,et al.Integrated microbiome,metabolome,and proteome analysis identifies a novel interplay among commensal bacteria,metabolites and candidate targets in non-small cell lung cancer［J］.Clin Transl Med,2022,12(6):e947 .
［63］SEGAL LN,CLEMENTE JC,TSAY JC,et al.Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a th17 phenotype［J］.Nat Microbiol,2016,1:16031.
［64］TANOUE T,MORITA S,PLICHTA DR,et al.A defined commensal consortium elicits CD8 T cells and anti-cancer immunity［J］.Nature,2019,565(7741):600-605.
［65］VARIAN BJ,GOURISHETTI S,POUTAHIDIS T,et al.Beneficial bacteria inhibit cachexia［J］.Oncotarget,2016,7 (11):11803-11816.
［66］GUTHRIE L,GUPTA S,DAILYJ,et al.Human microbiome signatures of differential colorectal cancer drug metabolism［J］.NPJ Biofilms Microbiomes,2017,3:27.

Memo

Memo:
山东省中医药科技发展计划项目（编号：2019-0503）；山东省滨州医学院科研启动基金（编号：BY2017KYQD14）
Last Update: 2023-12-29